Overview

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Status:
Not yet recruiting

Trial end date:
2025-07-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Nivolumab